Samsungbioepis Co,.Ltd
Samsung Bioepis Co., Ltd., a leading biopharmaceutical company headquartered in South Korea (KR), is renowned for its innovative approach in the biosimilars industry. Founded in 2012, the company has rapidly established itself as a key player in the global market, focusing on the development and commercialisation of high-quality biosimilars and biologics. With a strong presence in major operational regions including North America, Europe, and Asia, Samsung Bioepis offers a diverse portfolio of products that includes biosimilars for oncology and autoimmune diseases. Their commitment to rigorous research and development, combined with advanced manufacturing capabilities, sets them apart in a competitive landscape. Notable achievements include strategic partnerships with global pharmaceutical leaders, enhancing their market position and expanding access to affordable treatments. Samsung Bioepis continues to drive innovation, making significant contributions to the healthcare sector.
DitchCarbon Score
How does Samsungbioepis Co,.Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Samsungbioepis Co,.Ltd's score of 25 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Samsungbioepis Co,.Ltd's reported carbon emissions
In 2023, Samsung Bioepis Co., Ltd reported total carbon emissions of approximately 6,295,405 kg CO2e, comprising 1,209,479 kg CO2e from Scope 1 and 5,085,926 kg CO2e from Scope 2 emissions. This marked a slight increase from 2022, where emissions were about 6,200,000 kg CO2e. The company has demonstrated a commitment to reducing its carbon footprint, achieving a significant reduction from 2021's emissions of approximately 6,851,000 kg CO2e and 2020's 6,729,000 kg CO2e. Despite these reductions, there are currently no publicly disclosed reduction targets or climate pledges from Samsung Bioepis. The company has focused on improving its GHG emissions intensity, which has decreased from 0.0081 in 2021 to 0.0062 in 2023, indicating a more efficient operation relative to revenue. Samsung Bioepis continues to disclose its emissions data for Scope 1 and Scope 2, but has not provided information on Scope 3 emissions. The company’s ongoing efforts reflect a growing awareness of climate impact within the biopharmaceutical industry, aligning with global sustainability trends.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 1,433,412 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 5,296,110 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Samsungbioepis Co,.Ltd is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
